Micro RNA facilitated chemoresistance in gastric cancer: a novel biomarkers and potential therapeutics

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Balakrishnan M, George R, Sharma A, et al. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep. 2017;19(8):36.
   PubMedGoogle Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726.
   PubMed Web of Science ®Google Scholar
• Hamashima C, Shabana M, Okada K, et al. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015;106(12):1744–1749.
   PubMed Web of Science ®Google Scholar
• Deng JY, Liang H. Clinical significance of lymph node metastasis in gastric cancer. World J Gastroenterol. 2014;20(14):3967–3975.
   PubMed Web of Science ®Google Scholar
• Verma HK, Falco G, Bhaskar LVKS, Molecular Signaling Pathways Involved in Gastric Cancer Chemoresistance. In Theranostics Approaches to Gastric and Colon Cancer, Raju GSR, Bhaskar LVKS (eds.); Springer Singapore: Singapore, 2020; 117-134.
   Google Scholar
• Qi M, Liu D, Zhang S. MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer. Cancer Biomark. 2017;18(4):451–458.
   Web of Science ®Google Scholar
• Zeng J-F, Ma X-Q, Wang L-P, et al. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol. 2017;23(13):2337–2345.
   PubMed Web of Science ®Google Scholar
• Russi S, Verma HK, Laurino S, et al. Adapting and surviving: intra and extra-cellular remodeling in drug-resistant gastric cancer cells. Int J Mol Sci. 2019;20(15):3736.
   Web of Science ®Google Scholar
• da Silva Oliveira KC, Thomaz Araújo TM, Albuquerque CI, et al. Role of miRNAs and their potential to be useful as diagnostic and prognostic biomarkers in gastric cancer. World J Gastroenterol. 2016;22(35):7951–7962.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhuo H, Xu M, et al. Regulatory network of circRNA–miRNA–mRNA contributes to the histological classification and disease progression in gastric cancer. J Transl Med. 2018;16(1):216.
   PubMed Web of Science ®Google Scholar
• Hao N-B, He Y-F, Li X-Q, et al. The role of miRNA and lncRNA in gastric cancer. Oncotarget. 2017;8(46):81572–81582.
   PubMedGoogle Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. Embo J. 2004;23(20):4051–4060.
   PubMed Web of Science ®Google Scholar
• Schanen BC, Li X. Transcriptional regulation of mammalian miRNA genes. Genomics. 2011;97(1):1–6.
   Web of Science ®Google Scholar
• Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17(10):1712.
   PubMed Web of Science ®Google Scholar
• Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2007;96 Suppl:R40–R44.
   Google Scholar
• Feng Y, Bai F, You Y, et al. Dysregulated microRNA expression profiles in gastric cancer cells with high peritoneal metastatic potential. Exp Ther Med. 2018;16(6):4602–4608.
   Web of Science ®Google Scholar
• Li W, Ng JM-K, Wong CC, et al. Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer. Oncogene. 2018;37(36):4903–4920.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Q, Tang X. Long non-coding RNA XIST contributes into drug resistance of gastric cancer cell. Minerva Med. 2019;110(3):270–272.
   Web of Science ®Google Scholar
• Guo X, Wang X, Li S, et al. 27PLncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin. Ann Oncol. 2019;30(Supplement_5):v8.
   Google Scholar
• Song A-L, Zhao L, Wang Y-W, et al. Chemoresistance in gastric cancer is attributed to the overexpression of excision repair cross-complementing 1 (ERCC1) caused by microRNA-122 dysregulation. J Cell Physiol. 2019;234(12):22485–22492.
   Web of Science ®Google Scholar
• Xi Z, Si J, Nan J. LncRNA MALAT1 potentiates autophagyassociated cisplatin resistance by regulating the microRNA30b/autophagyrelated gene 5 axis in gastric cancer. Int J Oncol. 2019;54(1):239–248.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang R, Zhang S, et al. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. Gene. 2019;700:110–119.
   PubMed Web of Science ®Google Scholar
• Tao XC, Zhang X-Y, Sun S-B, et al. miR‑92a contributes to cell proliferation, apoptosis and doxorubicin chemosensitivity in gastric carcinoma cells. Oncol Rep. 2019;42(1):313–320.
   Web of Science ®Google Scholar
• Liu YP, Sun X-H, Cao X-L, et al. MicroRNA-217 suppressed epithelial-to-mesenchymal transition in gastric cancer metastasis through targeting PTPN14. Eur Rev Med Pharmacol Sci. 2017;21(8):1759–1767.
   Web of Science ®Google Scholar
• Zhu W, Xu H, Zhu D, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2012;69(3):723–731.
   PubMed Web of Science ®Google Scholar
• Wang T, Ge G, Ding Y, et al. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J (Engl). 2014;127(12):2357–2362.
   Web of Science ®Google Scholar
• Zhuang M, Shi Q, Zhang X, et al. Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Tumour Biol. 2015;36(4):2737–2745.
   Google Scholar
• Hu J, Fang Y, Cao Y, et al. miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci. 2014;59(2):336–345.
   PubMed Web of Science ®Google Scholar
• Wu H, Huang M, Lu M, et al. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013;71(5):1159–1171.
   Web of Science ®Google Scholar
• Sacconi A, Biagioni F, Canu V, et al. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 2012;3(11):e423.
   PubMedGoogle Scholar
• Li L-Q, Pan D, Chen Q, et al. Sensitization of gastric cancer cells to 5-FU by microRNA-204 through targeting the TGFBR2-mediated epithelial to mesenchymal transition. Cell Physiol Biochem. 2018;47(4):1533–1545.
   PubMedGoogle Scholar
• Li Y, Lv S, Ning H, et al. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother. 2018;108:1775–1782.
   PubMed Web of Science ®Google Scholar
• Yang M, Shan X, Zhou X, et al. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 2014;14(6):884–891.
   Web of Science ®Google Scholar
• Zhang Y, Qu X, Li C, et al. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol. 2015;36(4):2277–2285.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Z, Yu M, et al. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci. 2013;14(8):16226–16239.
   Web of Science ®Google Scholar
• Du Y, Zhu M, Zhou X, et al. miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB. Tumour Biol. 2016;37(1):1261–1269.
   PubMedGoogle Scholar
• Takagi T, Iio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and −145 in human gastric cancers. Oncology. 2009;77(1):12–21.
   Web of Science ®Google Scholar
• Wu Q, Yang Z, Xia L, et al. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget. 2014;5(22):11552–11563.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Shi H-J, Wang J-P, et al. MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. Int J Clin Exp Pathol. 2015;8(6):6397–6406.
   Web of Science ®Google Scholar
• Cheng Y, Lin C, Xin C, et al. [Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer]. Yi Chuan. 2014;36(2):119–126.
   Google Scholar
• An Y, Zhang Z, Shang Y, et al. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6(5):e1766.
   PubMedGoogle Scholar
• Li X, Liang J, Liu Y-X, et al. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.. Die Pharmazie. 2016;71(11):640–643.
   PubMed Web of Science ®Google Scholar
• Xu Y-C, Liu X, Li M, et al. A novel mechanism of doxorubicin resistance and tumorigenesis mediated by microRNA-501-5p-suppressed BLID. Mol Ther Nucleic Acids. 2018;12:578–590.
   PubMedGoogle Scholar
• Liu X, Lu Y, Xu Y, et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019;459:122–134.
   PubMed Web of Science ®Google Scholar
• Peng C, Huang K, Liu G, et al. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3. J Gastroenterol Hepatol. 2019;34(10):1711–1719.
   PubMed Web of Science ®Google Scholar
• Xue M, Li G, Sun P, et al. MicroRNA-613 induces the sensitivity of gastric cancer cells to cisplatin through targeting SOX9 expression. Am J Transl Res. 2019;11(2):885–894.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Dong Q, Wang E. MicroRNA-320 inhibits invasion and induces apoptosis by targeting CRKL and inhibiting ERK and AKT signaling in gastric cancer cells. Onco Targets Ther. 2017;10:1049–1058.
   PubMed Web of Science ®Google Scholar
• Pang X, Zhou Z, Yu Z, et al. Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain. RNA Biol. 2019;16(2):233–248.
   PubMed Web of Science ®Google Scholar
• Wang F, Song X, Li X, et al. Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system. PLoS One. 2013;8(4):e61792.
   Web of Science ®Google Scholar
• Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett. 2013;587(18):3069–3075.
   Web of Science ®Google Scholar
• Jingyue S, Xiao W, Juanmin Z, et al. TFAP2E methylation promotes 5fluorouracil resistance via exosomal miR106a5p and miR421 in gastric cancer MGC803 cells. Mol Med Rep. 2019;20(1):323–331.
   PubMed Web of Science ®Google Scholar
• Eto K, Iwatsuki M, Watanabe M, et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol. 2014;21(1):343–350.
   PubMed Web of Science ®Google Scholar
• Jin B, Liu Y, Wang H. Antagonism of miRNA-21 sensitizes human gastric cancer cells to paclitaxel. Cell Biochem Biophys. 2015;72(1):275–282.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhou X, Du Y, et al. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep. 2016;14(2):1742–1750.
   PubMed Web of Science ®Google Scholar
• Zhou X, Jin W, Jia H, et al. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res. 2015;34(1):28.
   Google Scholar
• Liu X, Ru J, Zhang J, et al. miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. PLoS One. 2013;8(6):e64707.
   PubMed Web of Science ®Google Scholar
• Hu Y, Song J, Liu L, et al. microRNA-4516 contributes to different functions of epithelial permeability barrier by targeting poliovirus receptor related protein 1 in Enterovirus 71 and Coxsackievirus A16 infections. Front Cell Infect Microbiol. 2018;8:110.
   Web of Science ®Google Scholar
• Lee SD, Yu D, Lee DY, et al. Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Cancer Sci. 2019;110(2):662-673.
   Google Scholar
• Lee SD, Yu D, Lee DY, et al. Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Cancer Sci. 2019;110(2):662–673.
   PubMed Web of Science ®Google Scholar
• Zhao T, Chen Y, Sheng S, et al. Upregulating microRNA-498 inhibits gastric cancer proliferation invasion and chemoresistance through inverse interaction of Bmi1. Cancer Gene Ther. 2019;26(11-12):366-373.
   Google Scholar
• Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German gastric cancer study. Ann Surg. 1998;228(4):449–461.
   PubMed Web of Science ®Google Scholar
• Seevaratnam R, Cardoso R, Mcgregor C, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer. 2012;15(Suppl S1):S3–S18.
   Google Scholar
• Zubarayev M, Min E-K, Son T. Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. Transl Gastroenterol Hepatol. 2019;4:59.
   PubMed Web of Science ®Google Scholar
• Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272–286.
   PubMed Web of Science ®Google Scholar
• Yu BQ, Su LP, Li JF, et al. microRNA expression signature of gastric cancer cells relative to normal gastric mucosa. Mol Med Rep. 2012;6(4):821–826.
   Web of Science ®Google Scholar
• Chen L, Jiang M, Yuan W, et al. Prognostic value of miR-93 overexpression in resectable gastric adenocarcinomas. Acta Gastro-enterologica Belgica. 2012;75(1):22–27.
   Web of Science ®Google Scholar
• Zhang L, Huang Z, Zhang H, et al. Prognostic value of candidate microRNAs in gastric cancer: A validation study. Cancer Biomark. 2017;18(3):221–230.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liang Y, Ma MH, et al. Downregulation of microRNA-376a in gastric cancer and association with poor prognosis. Cell Physiol Biochem. 2018;51(5):2010–2018.
   Google Scholar
• Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese gastric cancer association. Gastric Cancer. 2014;17(1):26–33.
   PubMed Web of Science ®Google Scholar
• Yan W, Wang S, Sun Z, et al. Identification of microRNAs as potential biomarker for gastric cancer by system biological analysis. Biomed Res Int. 2014;2014:901428.
   Web of Science ®Google Scholar
• Shin VY, Ng EKO, Chan VW, et al. A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Mol Cancer. 2015;14(1):202.
   PubMedGoogle Scholar
• Huang Y, Zhu J, Li W, et al. Serum microRNA panel excavated by machine learning as a potential biomarker for the detection of gastric cancer. Oncol Rep. 2018;39(3):1338–1346.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Jeong S, Jung WY, et al. miRNAs as potential biomarkers for the progression of gastric cancer inhibit CREBZF and regulate migration of gastric adenocarcinoma cells. Int J Med Sci. 2020;17(6):693–701.
   Web of Science ®Google Scholar
• Mei J-W, Yang Z-Y, Xiang H-G, et al. MicroRNA-1275 inhibits cell migration and invasion in gastric cancer by regulating vimentin and E-cadherin via JAZF1. BMC Cancer. 2019;19(1):740.
   PubMedGoogle Scholar
• Wang L, Wang X, Jiang X. miR-127 suppresses gastric cancer cell migration and invasion via targeting Wnt7a. Oncol Lett. 2019;17(3):3219–3226.
   Web of Science ®Google Scholar
• Xu J, Wang F, Wang X, et al. miRNA-543 promotes cell migration and invasion by targeting SPOP in gastric cancer. Onco Targets Ther. 2018;11:5075–5082.
   Web of Science ®Google Scholar
• Qiu X, Zhu H, Liu S, et al. Expression and prognostic value of microRNA-26a and microRNA-148a in gastric cancer. J Gastroenterol Hepatol. 2017;32(4):819–827.
   Web of Science ®Google Scholar
• Wang J, Zhang J, Wu J, et al. MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein. Eur J Cancer. 2012;48(12):1904–1913.
   PubMed Web of Science ®Google Scholar
• Lu Q, Chen Y, Sun D, et al. MicroRNA-181a functions as an oncogene in gastric cancer by targeting Caprin-1. Front Pharmacol. 2019;9(1565). DOI:10.3389/fphar.2018.01565.
   Google Scholar
• Alessandrini L, Manchi M, De Re V, et al. Proposed molecular and miRNA classification of gastric cancer. Int J Mol Sci. 2018;19(6):1683.
   Web of Science ®Google Scholar
• Jiang Z, Guo J, Xiao B, et al. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol. 2010;45(1):17–23.
   PubMed Web of Science ®Google Scholar
• Yepes S, López R, Andrade RE, et al. Co-expressed miRNAs in gastric adenocarcinoma. Genomics. 2016;108(2):93–101.
   Web of Science ®Google Scholar
• Pereira A, Moreira F, Vinasco-Sandoval T, et al. miRNome reveals new insights into the molecular biology of field cancerization in gastric cancer. Front Genet. 2019;10(592). DOI:10.3389/fgene.2019.00592.
   Google Scholar
• Azarbarzin S, Safaralizadeh R, Kazemzadeh M, et al. The value of miR-383, an intronic miRNA, as a diagnostic and prognostic biomarker in intestinal-type gastric cancer. Biochem Genet. 2017;55(3):244–252.
   PubMed Web of Science ®Google Scholar
• Kim SY, Jeon TY, Choi CI, et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagn. 2013;15(5):661–669.
   PubMed Web of Science ®Google Scholar
• Chu D, Zhao Z, Li Y, et al. Increased microRNA-630 expression in gastric cancer is associated with poor overall survival. PLoS One. 2014;9(3):e90526.
   Web of Science ®Google Scholar
• Tsai -M-M, Wang C-S, Tsai C-Y, et al. MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. Cancer Lett. 2014;351(2):222–231.
   PubMed Web of Science ®Google Scholar
• Gong J, Li J, Wang Y, et al. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis. 2014;35(2):497–506.
   PubMed Web of Science ®Google Scholar
• Wu J, Li G, Wang Z, et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis Markers. 2015;2015:435656.
   PubMed Web of Science ®Google Scholar
• Yuan C, Zhang Y, Tu W, et al. Integrated miRNA profiling and bioinformatics analyses reveal upregulated miRNAs in gastric cancer. Oncol Lett. 2019;18(2):1979–1988.
   Web of Science ®Google Scholar
• Yang Y, Qu A, Zhao R, et al. Genome-wide dentification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. Mol Oncol. 2018;12(12):2072–2084.
   Web of Science ®Google Scholar
• Yan Z, Xiong Y, Xu W, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012;7(7):e40037.
   Web of Science ®Google Scholar
• Imaoka H, Toiyama Y, Okigami M, et al. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer. 2016;19(3):744–753.
   PubMed Web of Science ®Google Scholar
• Hou CG, Luo XY, Li G. Diagnostic and prognostic value of serum microRNA-206 in patients with gastric cancer. Cell Physiol Biochem. 2016;39(4):1512–1520.
   PubMedGoogle Scholar
• Zhang X, Yan Z, Zhang J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol. 2011;22(10):2257–2266.
   PubMed Web of Science ®Google Scholar
• Xue H-G, Yang AH, Sun XG, et al. Expression of microRNA-328 functions as a biomarker for recurrence of early gastric cancer (EGC) after endoscopic submucosal dissection (ESD) by modulating CD44. Med Sci Monit. 2016;22:4779–4785.
   Web of Science ®Google Scholar
• Bras-Rosario L, Matsuda A, Pinheiro AI, et al. Expression profile of microRNAs regulating proliferation and differentiation in mouse adult cardiac stem cells. PLoS One. 2013;8(5):e63041.
   Web of Science ®Google Scholar
• Wang F, Li T, Zhang B, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013;434(3):688–694.
   PubMed Web of Science ®Google Scholar
• Fang Y, Shen H, Li H, et al. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013;45(11):963–972.
   Web of Science ®Google Scholar
• Yang S-M, Huang C, Li X-F, et al. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013;306:162–168.
   PubMed Web of Science ®Google Scholar
• Deng H, Guo Y, Song H, et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013;518(2):351–359.
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–379.
   PubMed Web of Science ®Google Scholar
• Shang Y, Zhang Z, Liu Z, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33(25):3267–3276.
   PubMed Web of Science ®Google Scholar
• Zhu W, Shan X, Wang T, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127(11):2520–2529.
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhu D, Lu S, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29(1):384–391.
   PubMed Web of Science ®Google Scholar
• Zhang F, Li K, Yao X, et al. A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine. 2019;44:311–321.
   PubMed Web of Science ®Google Scholar
• Zhu X, Lv M, Wang H, et al. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. Dig Dis Sci. 2014;59(5):911–919.
   PubMed Web of Science ®Google Scholar
• Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113(4):569–573.
   PubMed Web of Science ®Google Scholar
• Riquelme I, Letelier P, Riffo-Campos A, et al. Emerging role of miRNAs in the drug resistance of gastric cancer. Int J Mol Sci. 2016;17(3):424.
   PubMed Web of Science ®Google Scholar
• Wang R, Ma J, Wu Q, et al. Functional role of miR-34 family in human cancer. Curr Drug Targets. 2013;14(10):1185–1191.
   Web of Science ®Google Scholar
• Misso G, Di Martino MT, De Rosa G, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194.
   PubMedGoogle Scholar
• Zhang DG, Zheng JN, Pei DS. P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy. Mol Cancer. 2014;13(1):115.
   Google Scholar
• Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8(1):266.
   PubMedGoogle Scholar
• Wang A-M, Huang -T-T, Hsu K-W, et al. Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget. 2014;5(13):5002–5016.
   PubMedGoogle Scholar
• Kim CH, Kim HK, Rettig RL, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics. 2011;4(1):79.
   PubMedGoogle Scholar
• Smid D, KULDA V, SRBECKA K, et al. Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. Int J Oncol. 2016;48(6):2693–2703.
   Web of Science ®Google Scholar
• Lu C, Shan Z, Li C, et al. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 2017;86:450–456.
   PubMed Web of Science ®Google Scholar
• Li X, Lv Y, Hao J, et al. Role of microRNA-4516 involved autophagy associated with exposure to fine particulate matter. Oncotarget. 2016;7(29):45385–45397.
   PubMedGoogle Scholar
• Chun-Zhi Z, Lei H, An-ling Z, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10(1):367.
   PubMedGoogle Scholar
• Xiong X, Ren H-Z, Li M-H, et al. Down-regulated miRNA-214 induces a cell cycle G1 arrest in gastric cancer cells by up-regulating the PTEN protein. Pathol Oncol Res. 2011;17(4):931–937.
   PubMed Web of Science ®Google Scholar
• Zhang BG, LI JF, YU BQ, et al. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep. 2012;27(4):1019–1026.
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010;70(6):2339–2349.
   PubMed Web of Science ®Google Scholar
• Li L, Zhu X, Shou T, et al. MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway. Mol Med Rep. 2018;17(3):4003–4010.
   PubMed Web of Science ®Google Scholar
• Li GQ, Xie J, Lei X-Y, et al. Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway. World J Gastroenterol. 2009;15(44):5541–5548.
   Web of Science ®Google Scholar
• Bandres E, Bitarte N, Arias F, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009;15(7):2281–2290.
   PubMed Web of Science ®Google Scholar
• Liu F, Yang X, Geng M, et al. Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018;8(4):552–562.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Akiyama Y, Otsubo T, et al. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 2010;31(5):777–784.
   Web of Science ®Google Scholar
• Lang N, Liu M, Tang Q-L, et al. Effects of microRNA-29 family members on proliferation and invasion of gastric cancer cell lines. Chin J Cancer. 2010;29(6):603–610.
   Google Scholar
• Feng L, Xie Y, Zhang H, et al. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2012;29(2):856–863.
   PubMed Web of Science ®Google Scholar
• Zhang J-X, Xu Y, Gao Y, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 2017;16(1):18.
   PubMed Web of Science ®Google Scholar
• Dickinson RE, Dallol A, Bieche I, et al. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer. 2004;91(12):2071–2078.
   PubMed Web of Science ®Google Scholar
• Mehlen P, Delloye-Bourgeois C, Chédotal A. Novel roles for Slits and netrins: axon guidance cues as anticancer targets? Nature Reviews Cancer. 2011;11(3):188–197.
   PubMed Web of Science ®Google Scholar
• Tie J, Pan Y, Zhao L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010;6(3):e1000879.
   PubMed Web of Science ®Google Scholar
• Kim M, KIM J-H, BAEK S-J, et al. Specific expression and methylation of SLIT1, SLIT2, SLIT3, and miR-218 in gastric cancer subtypes. Int J Oncol. 2016;48(6):2497–2507.
   Web of Science ®Google Scholar
• Bousoik E, Montazeri Aliabadi H. “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway. Front Oncol. 2018;8(287). DOI:10.3389/fonc.2018.00287
   Google Scholar
• Furqan M, Mukhi N, Lee B, et al. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013;1(1):5.
   PubMedGoogle Scholar
• Ding L, Xu Y, Zhang W, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20(7):784–793.
   PubMed Web of Science ®Google Scholar
• Wu H, Huang M, Cao P, et al. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther. 2012;13(5):281–288.
   PubMed Web of Science ®Google Scholar
• Wu W, Takanashi M, Borjigin N, et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer. 2013;108(3):653–661.
   Web of Science ®Google Scholar
• Xiao C, Hong H, Yu H, et al. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway. Immunopharmacol Immunotoxicol. 2018;40(4):278–283.
   PubMed Web of Science ®Google Scholar
• He T-C, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–1512.
   PubMed Web of Science ®Google Scholar
• Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96(10):5522–5527.
   PubMed Web of Science ®Google Scholar
• Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006;66(3):1277–1281.
   PubMed Web of Science ®Google Scholar
• Kim K, Lee H-C, Park J-L, et al. Epigenetic regulation of microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer. Epigenetics. 2011;6(6):740–751.
   PubMed Web of Science ®Google Scholar
• Liu M, Yang S, Wang Y, et al. EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis. Mol Carcinog. 2009;48(3):212–219.
   Web of Science ®Google Scholar
• Zhang Z, Liu S, Shi R, et al. miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. Cancer Genet. 2011;204(9):486–491.
   PubMed Web of Science ®Google Scholar
• Zhou H, Wang K, Hu Z, et al. TGF-beta1 alters microRNA profile in human gastric cancer cells. Chin J Cancer Res. 2013;25(1):102–111.
   PubMed Web of Science ®Google Scholar
• Liu D, Hu X, Zhou H, et al. Identification of aberrantly expressed miRNAs in gastric cancer. Gastroenterol Res Pract. 2014;2014:473817.
   PubMed Web of Science ®Google Scholar